Clinical trials: Plasma Cell Mediated, active
IgM MGUS, Waldenstrom Macroglobulinemia
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
In this research study, is combining a new treatment acalabrutinib with a standard treatment, rituximab or other CD20 antibody, to determine whether this combination is safe and effective for participants with Immunoglobulin (Ig)…
- Conditions
- IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral
- Trial name
- NCT05065554
- Testing
- Acalabrutinib, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Shayna Sarosiek, MD
Oral Submucous Fibrosis
Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis
Oral Submucous Fibrosis (OSF) is a chronic, progressive, potentially malignant disorder characterized by mucosal stiffness, trismus, and burning sensation.
- Trial name
- RegenOSF (NCT07277998)
- Testing
- Platelet-Rich Plasma (PRP) Injections, Triamcinolone Acetonide
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Karachi Medical and Dental College
Food Allergy
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy.
- Trial name
- NCT06369467
- Testing
- linvoseltamab, dupilumab
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Regeneron Pharmaceuticals